Somewhat Favorable News Coverage Somewhat Unlikely to Impact Paratek Pharmaceuticals (PRTK) Stock Price
News coverage about Paratek Pharmaceuticals (NASDAQ:PRTK) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 45.7445884463903 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- Water Island Capital LLC Acquires 85,000 Shares of Paratek Pharmaceuticals Inc (PRTK) (americanbankingnews.com)
- Raymond James Financial Reiterates Outperform Rating for Paratek Pharmaceuticals (PRTK) (americanbankingnews.com)
- HC Wainwright Boosts Paratek Pharmaceuticals (PRTK) Price Target to $55.00 (americanbankingnews.com)
- Paratek Pharmaceuticals Inc Forecasted to Earn Q1 2019 Earnings of ($3.54) Per Share (PRTK) (americanbankingnews.com)
- Paratek Pharmaceuticals (PRTK) Announces Earnings Results (americanbankingnews.com)
Paratek Pharmaceuticals (NASDAQ:PRTK) traded up $0.35 during trading on Friday, hitting $13.15. 666,295 shares of the stock were exchanged, compared to its average volume of 592,613. Paratek Pharmaceuticals has a 12-month low of $11.85 and a 12-month high of $29.00. The company has a debt-to-equity ratio of 0.49, a quick ratio of 10.53 and a current ratio of 10.53. The company has a market cap of $377.47, a P/E ratio of -3.91 and a beta of 0.40.
Several brokerages have commented on PRTK. Raymond James Financial reiterated an “outperform” rating and issued a $36.00 price target on shares of Paratek Pharmaceuticals in a research note on Friday. BidaskClub cut shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 2nd. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Thursday, February 22nd. UBS Group cut shares of Paratek Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research note on Friday. Finally, ValuEngine cut shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 29th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $40.75.
In other news, CFO Douglas W. Pagan sold 16,291 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $14.22, for a total value of $231,658.02. Following the sale, the chief financial officer now directly owns 39,570 shares in the company, valued at approximately $562,685.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Evan Loh sold 3,040 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $14.22, for a total transaction of $43,228.80. Following the completion of the sale, the chief operating officer now owns 144,870 shares in the company, valued at $2,060,051.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,664 shares of company stock worth $573,226. Insiders own 4.90% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Paratek Pharmaceuticals (PRTK) Stock Price” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/03/03/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-paratek-pharmaceuticals-prtk-stock-price.html.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.